Artiva Biotherapeutics (ARTV) – Investment Analysts’ Recent Ratings Changes

Artiva Biotherapeutics (NASDAQ: ARTV) has recently received a number of price target changes and ratings updates:

• 3/26/2025 – Artiva Biotherapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
• 3/25/2025 – Artiva Biotherapeutics had its price target lowered by analysts at Cantor Fitzgerald from $23.00 to $20.00. They now have an “overweight” rating on the stock.
• 3/25/2025 – Artiva Biotherapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
• 3/25/2025 – Artiva Biotherapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock opened at $3.31 on Tuesday. Artiva Biotherapeutics, Inc. has a 52 week low of $2.19 and a 52 week high of $17.31. The company’s 50 day moving average price is $4.29 and its two-hundred day moving average price is $8.86.

Institutional Investors Weigh In On Artiva Biotherapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $7,435,000. Geode Capital Management LLC increased its stake in shares of Artiva Biotherapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company’s stock worth $3,184,000 after purchasing an additional 6,828 shares during the last quarter. Wellington Management Group LLP acquired a new stake in shares of Artiva Biotherapeutics in the third quarter valued at approximately $2,912,000. Northern Trust Corp boosted its stake in shares of Artiva Biotherapeutics by 3.8% during the 4th quarter. Northern Trust Corp now owns 117,112 shares of the company’s stock worth $1,180,000 after acquiring an additional 4,335 shares during the period. Finally, State Street Corp acquired a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $1,337,000.

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.